Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 19, 2026.

Bacteroides fragilis Lipopolysaccharide and Inflammatory Signaling in Alzheimer’s Disease

Walter J. Lukiw

Frontiers in Microbiology · 2016

doi:10.3389/fmicb.2016.01544

Abstract

The human microbiome consists of ~3.8x1013 symbiotic microorganisms that form a highly complex and dynamic ecosystem: the gastrointestinal (GI) tract constitutes the largest repository of the human microbiome by far, and its impact on human neurological health and disease is becoming increasingly appreciated. Bacteroidetes, the largest phylum of gram-negative bacteria in the GI tract microbiome, while generally beneficial to the host when confined to the GI tract, have potential to secrete a remarkably complex array of pro-inflammatory neurotoxins that include surface lipopolysaccharides (LPSs) and toxic proteolytic species. The deleterious effects of these bacterial exudates appear to become more important as GI tract and blood-brain barriers alter or increase their permeability with aging and disease. For example, presence of the unique LPSs of the abundant Bacteroidetes species Bacteroides fragilis (BF-LPS) in the serum represents a major contributing factor to systemic inflammation. BF-LPS is further recognized by TLR2, TLR4 and/or CD14 microglial cell receptors as are the pro-inflammatory 42 amino acid amyloid-beta (Aβ42) peptides that characterize Alzheimer’s disease (AD) brain. Here we provide the first evidence that BF-LPS exposure to human primary brain cells is an exceptionally potent inducer of the pro-inflammatory transcription factor NF-kB (p50/p65) complex, a known trigger in the expression of pathogenic pathways involved in inflammatory neurodegeneration. This ‘Perspectives communication’ will in addition highlight work from recent studies that advance novel and emerging concepts on the potential contribution of microbiome-generated factors, such as BF-LPS, in driving pro-inflammatory degenerative neuropathology in the AD brain.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

The Human Microbiome and Bacteroides fragilis

Homo sapiens and their complex microbiome, consisting chiefly of bacteria with microbial eukaryotes, archaea, fungi, protozoa, viruses, and other microorganisms making up the balance, together compromise the entire metaorganism whose symbiotic associations and host interactions are critical to human health and disease. There are approximately 52 recognized divisions of bacteria, however, humans, have co-evolved with – 2 dominant phyla: Bacteroidetes [about 20% of all gastrointestinal (GI) tract bacteria] and Firmicutes (about 80%); with Actinobacteria (about 3%), Proteobacteria (~1%), and Verrucomicrobia (~0.1%) making up significantly smaller fractions. These four major bacterial divisions represent the ‘bacterial-core’ of the human microbiome. About 98% of GI tract microbiota consists of anaerobic bacteria, and Bacteroidetes species, constituting ~30% of all GI tract bacteria are the most abundant Gram-negative bacteria found in the GI tract outnumbering Escherichia coli abundance by at least 100 to 1.

Bacteroidetes species such as Bacteroides fragilis, normal commensals of the GI tract, are thought to be generally beneficial to human health via their production of polysaccharides, volatile fatty acids, cleavage of dietary fibers into digestible short-chain fatty acids, and other nutrients, however, when they escape this environment they can cause substantial inflammatory pathology with significant morbidity and mortality. Dietary intake may have a role in regulating the composition and stoichiometry of the GI tract microbiome; for example Bacteroidetes species have been observed to proliferate in porcine models fed high-fat diets deprived of sufficient dietary fiber. In addition to their lipopolysaccharide (LPS) generation, B. fragilis endotoxins are a leading cause of anaerobic bacteremia and sepsis/systemic inflammatory distress through their generation of the highly pro-inflammatory zinc metalloprotease metalloproteinase B. fragilis toxin (BFT) fragilysin. BFT has recently been shown to disrupt epithelial cells of GI tract barriers via cleavage of the synaptic adhesion zonula adherens protein E-cadherin. It is currently not well understood if GI tract barrier-disrupting proteolytic endotoxins such as BFT are able to propagate pathogenic actions via the systemic circulation to further disrupt the blood-brain barrier and transfer LPS, BFT, and other endotoxins into the cerebrovascular circulation to the neural cells and synaptic circuitry of the CNS. B. fragilis has been shown to play a pathological role in neurodevelopment including autism spectrum disorder (ASD) via circulating metabolites. It has also recently been reported that along with BFTs amyloid peptide-dependent changes in synaptic adhesion affect both the function and integrity of synapses, suggesting that the observed deficits in synaptic adhesion in Alzheimer’s disease (AD) play key roles in the progressive disruption of functional signaling throughout neuronal networks.

Inflammatory Signaling in Alzheimer’s Disease (AD)

Multiple and highly interactive aspects of increased inflammatory signaling is a consistent and recurrent feature of AD and the major pathological lesions that define AD, including insoluble Aβ42-enriched peptide deposits, neurofibrillary tangles, apoptotic, damaged, and dying neurons, and activated microglia are potent neuropathological stimulants that maintain the brain in a chronic and self-reinforcing inflammatory state. These progressive and ultimately fatal pro-inflammatory and neurodegenerative processes appear to be further stimulated by aberrant or excessive deregulation of the innate-immune response, and an increasing focus has been placed on pathological contributions by the human microbiome including dietary effects on microbial composition that appear to support pathological functions. There is a wealth of accumulating evidence (a) that specific types of microbial LPS and endotoxins (such as BF-LPS and BFT) from enterotoxigenic microbes specifically impact microglial-mediated innate-immune responses, phagocytic, and detoxifying mechanisms and amyloidogenesis characteristic of inflammatory neurodegeneration; and (b) a resurgence of our interest in the importance of GI tract and blood-brain barrier systems that normally exclude these microbiome-sourced toxins from the systemic circulation and CNS but become leaky with age and disease.

Interestingly, while secreted LPS, proteolytic endotoxins, and amyloid monomers are generally soluble as monomers over time they form into highly insoluble fibrous protein aggregates that are implicated in the progressive degenerative neuropathology of several common, age-related disorders of the human systemic circulation and CNS including systemic inflammation response syndrome, multiple sclerosis (MS), prion disease, and AD. At the genetic level, virtually all of this inducible inflammatory signaling within the CNS involves NF-kB activation and NF-kB-recognition and binding to target NF-kB DNA sequences as a prelude to the up-regulation of pro-inflammatory gene expression pathways, including the up-regulation of discrete families of pro-inflammatory pathogenic microRNAs that selectively down-regulate their mRNA targets.

Lipopolysaccharide (LPS) and LPS Signaling

Lipopolysaccharides are characteristic components of the outer leaflet of the outer membrane of Gram-negative bacteria shed into the extracellular space that play key roles in host–pathogen interactions of the innate-immune system. While LPSs contain large and hypervariable polysaccharide/oligosaccharide regions, the relatively conserved lipid region (lipid A) is the endotoxic and biologically active moiety that is responsible for septic shock. A “canonical” LPS structure is represented by that of LPS from E. coli, that contains one of the most potent neurotoxic lipid A species known, consisting of a 1,4′-biphosphorylated glucosamine disaccharide bearing six fatty acids which are unbranched chains 12–14 methyl(ene) units in length. Other ‘lipid A’ species show variability in the number, length, and composition of the attached fatty acids, as well as variability in the degree of phosphorylation and number and types of substituted phosphate ligands. For instance, BF-LPS lipid A is penta-acylated and mono-phosphorylated and contains branched fatty acids 15–17 methyl(ene) units in length; deviations from the canonical lipid A structure are known to have a profound impact on the host innate-immune responses. LPS activates Toll-like receptors (TLRs), membrane-spanning protein receptors expressed in microglial cells of the innate immune system which recognize common damage- or pathogen-associated molecular-patterns (DAMPS, PAMPs;;;;;; ). TLRs play key roles in host protection from microbial invasion via the activation of the innate-immune system by sensing structurally conserved DAMPS or PAMPs from microbes or microbial exudates that are distinguishable from, and not innate to, the host organism. Interestingly, of the 13 currently characterized TLRs the microglial TLR2 and TLR4 are activated by amyloid, LPS, lipoglycans and/or other microbial triggers that subsequently induce cytokine production, inflammation, phagocytosis and innate immune defense responses that directly impact the development of CNS pathology. More specifically, the TLR2 complex can recognize biofilm-associated LPS and amyloids produced by both Bacteroidetes and Firmicutes. Interestingly, Aβ42 peptides overproduced in AD that are associated with microglia-mediated inflammatory responses have very recently been shown to activate TLR2 and/or TLR4. Of further interest is: (a) that microbial amyloids induce pro-inflammatory interleukin IL-17A and IL-22, triggers for NF-kB activation/signaling and cyclooxygenase 2 activation via direct TLR2 activation; and (b) that increased levels of both IL-17A and IL-22 are associated with age-related inflammatory neurodegenerative diseases such as AD. Bacterial endotoxin- and LPS-induced neuro-inflammation has been known for some time to be important in driving the generation of Aβ42. In addition to TLR2 and TLR4 at least one additional microglial transmembrane LPS receptor CD14 mediates phagocytosis of both bacterial components and Aβ42 peptides, hence expanding roles for microglia and microglial LPS receptors in the pathophysiology of AD. Of further interest is that gram negative bacterial exudates such as BF-LPS are hypervariable in composition, and different Bacteroidetes species appear to generate unique temporal patterns of LPS that exhibit rapid adaptive changes – these include the modulation of LPS synthesis and structure and alterations in DAMP/PAMP recognition features as strategies for host immune system evasion.

Concluding Remarks

We hope that this ‘Perspectives’ article has adequately highlighted some recent findings on microbial-derived LPS and proteolytic endotoxins and has engendered interest in the potential contribution of these neurotoxic and pro-inflammatory microbial exudates to amyloidogenesis and age-related inflammatory neurodegeneration. Taken together, these current observations advance seven key areas in our understanding of the role of the microbiome in progressive, age-related inflammatory neurodegeneration: (a) that relatively low, nanomolar amounts of bacterial LPS are extremely potent inducers of the pro-inflammatory transcription factor NF-kB (p50/p65 complex) in human primary human neuronal-glial (HNG) co-cultures of brain cells (Figure 1); (b) that different LPS preparations from different bacterial species appear to exhibit slightly different trends in the induction of an inflammatory response, as quantified by the extent (mean values) of NF-kB activation and DNA-binding (Figure 1); (c) that the proliferation of microbial species such as the BF-LPS and BFT generating Bacteroidetes may be regulated by diet, environment, and lifestyle factors such as dietary fiber intake can impact neurological health, CNS inflammation, and degenerative disease; (d) that LPS transit across compromised GI tract and blood-brain barriers underscore the critical roles of cellular adhesion structures in allowing passage of noxious molecules from the GI tract into the systemic circulation and CNS; (e) that biophysical, gastrointestinal, and neurobiological barriers which may become more ‘leaky’ with aging again underscore the important role of tight junctions in moderating systemic and CNS inflammation and immune-mediated inflammatory disease; (f) that DAMPS and/or PAMPs common to both LPS, endotoxins, and/or amyloid may trigger TRL2, TRL4 and/or CD14 microglial receptors to propagate and sustain inducible AD-relevant inflammatory responses within the CNS; and (g) that LPS abundance, speciation and complexity in the CSF and/or blood serum may be useful diagnostically for the onset of mild cognitive impairment (MCI), the clinical precursor for the development of AD. Clearly, more research into the intriguing realm of human microbiome-host interaction is warranted, and the study of the complex interactions between each biological niche is certain to shed new light on the still evolving concepts and mechanisms of microbiome interplay and control in human neurological health and disease.

Author Contributions

WL and the late Dr. James Hill performed experiments, researched and wrote this paper; the author is sincerely grateful to colleagues and collaborators for helpful discussions, medical artwork and unpublished data; the contributions of these researchers have been recognized in the ‘Acknowledgements’ section.

Conflict of Interest Statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 48

  1. 1.

    Asti A. Gioglio L. (2014 ). Can a bacterial endotoxin be a key factor in the kinetics of amyloid fibril formation? J. Alzheimers Dis. 39 169–179.

    Not in our library10.3233/jad-131394

  2. 2.
  3. 3.

    Calsolaro V. Edison P. (2016 ). Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement. 12 719–732.

    Not in our library10.1016/j.jalz.2016.02.010

  4. 4.

    Choi V. M. Herrou J. Hecht A. L. Teoh W. P. Turner J. R. Crosson S. (2016 ). Activation of Bacteroides fragilis toxin by a novel bacterial protease contributes to anaerobic sepsis in mice. Nat. Med. 22 563–567.

    Not in our library10.1038/nm.4077

  5. 5.

    Clark I. A. Vissel B. (2015 ). Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer’s disease. Br. J. Pharmacol. 172 3714–3727.

    Not in our library10.1111/bph.13181

  6. 6.

    Clement C. Hill J. M. Dua P. Culicchia F. Lukiw W. J. (2016 ). Analysis of RNA from Alzheimer’s disease post-mortem brain tissues. Mol. Neurobiol. 53 1322–1328.

    Not in our library10.1007/s12035-015-9105-6

  7. 7.

    Devier D. J. Lovera J. F. Lukiw W. J. (2015 ). Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration. Front. Mol. Neurosci. 8:5

    Not in our library10.3389/fnmol.2015.00005

  8. 8.

    Eidhin D. N. Mouton C. (1993 ). A rapid method for preparation of rough and smooth lipopolysaccharide from Bacteroides, Porphyromonas and Prevotella. FEMS Microbiol. Lett. 110 133–138.

    Not in our library10.1111/j.1574-6968.1993.tb06309.x

  9. 9.

    Fathi P. Wu S. (2016 ). Isolation, detection, and characterization of enterotoxigenic Bacteroides fragilis in clinical samples. Open Microbiol. J. 10 57–63.

    Not in our library10.2174/1874285801610010057

  10. 10.

    Foster J. A. Lyte M. Meyer E. Cryan J. F. (2016 ). Gut microbiota and brain function: an evolving field in neuroscience. Int. J. Neuropsychopharmacol. 19 yv114.

    Not in our library10.1093/ijnp/pyv114

  11. 11.

    Gustot A. Raussens V. Dehousse M. Dumoulin M. Bryant C. E. Ruysschaert J. M. (2013 ). Activation of innate immunity by lysozyme fibrils is critically dependent on cross-β sheet structure. Cell. Mol. Life. Sci. 70 2999–3012.

    Not in our library10.1007/s00018-012-1245-5

  12. 12.
  13. 13.

    Halmer R. Davies L. Liu Y. Fassbender K. Walter S. (2015 ). The innate immune receptor CD14 mediates lymphocyte migration in EAE. Cell. Physiol. Biochem. 37 269–275.

    Not in our library10.1159/000430351

  14. 14.

    Heinritz S. N. Weiss E. Eklund M. Aumiller T. Heyer C. M. Messner S. (2016 ). Impact of a high-fat or high-fiber diet on intestinal microbiota and metabolic markers in a pig podel. Nutrients 8:E317

    Not in our library10.3390/nu8050317

  15. 15.
  16. 16.
  17. 17.

    Hofer U. (2014 ). Microbiome: B. fragilis and the brain. Nat. Rev. Microbiol. 12 76–77.

    Not in our library10.1038/nrmicro3197

  18. 18.

    Hug L. A. Baker B. J. Anantharaman K. Brown C. T. Probst A. J. Castelle C. J. (2016 ). A new view of the tree of life. Nat. Microbiol. 1:16048

    Not in our library10.1038/nmicrobiol.2016.48

  19. 19.

    Hugon P. Dufour J. C. Colson P. Fournier P. E. Sallah K. Raoult D. (2015 ). A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect. Dis. 15 1211–1219.

    Not in our library10.1016/s1473-3099(15)00293-5

  20. 20.

    Jiang Q. Jin S. Jiang Y. Liao M. Feng R. Zhang L. (2016 ). Alzheimer’s disease variants with the genome-wide significance are significantly enriched in immune pathways and active in immune cells. Mol. Neurobiol. [Epub ahead of print].

    Not in our library10.1007/s12035-015-9670-8

  21. 21.

    Khanna S. Tosh P. K. (2014 ). A clinician’s primer on the role of the microbiome in human health and disease. Mayo Clin. Proc. 89 107–114.

    Not in our library10.1016/j.mayocp.2013.10.011

  22. 22.

    Land W. G. (2015 ). The role of damage-associated molecular patterns (DAMPs) in human diseases: part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine. Sultan Qaboos Univ. Med. J. 15 e157–e170.

    Not in our library

  23. 23.
  24. 24.

    Leshchyns’ka I. Sytnyk V. (2016 ). Synaptic cell adhesion molecules in Alzheimer’s disease. Neural Plast. 2016 6427537

    Not in our library10.1155/2016/6427537

  25. 25.

    Lim S. L. Rodriguez-Ortiz C. J. Kitazawa M. (2015 ). Infection, systemic inflammation, and Alzheimer’s disease. Microbes Infect. 17 549–556.

    Not in our library10.1016/j.micinf.2015.04.004

  26. 26.

    Lin C. S. Chang C. J. Lu C. C. Martel J. Ojcius D. M. Ko Y. F. (2014 ). Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. Biomed. J. 37 259–268.

    Not in our library10.4103/2319-4170.138314

  27. 27.

    Lukiw W. J. Bazan N. G. (1998 ). Strong NF-kB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer’s disease superior temporal lobe neocortex. J. Neurosci. Res. 53 583–592.

    Not in our library10.1002/(sici)1097-4547(19980901)53:5<583::aid-jnr8>3.0.co;2-5

  28. 28.

    Lukiw W. J. Zhao Y. Cui J. G. (2008 ). An NF-kB-sensitive microRNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J. Biol. Chem. 283 31315–31322.

    Not in our library10.1074/jbc.m805371200

  29. 29.

    Maldonado R. F. Sá-Correia I. Valvano M. A. (2016 ). Lipopolysaccharide modification in Gram-negative bacteria during chronic infection. FEMS Microbiol. Rev. 40 480–493.

    Not in our library10.1093/femsre/fuw007

  30. 30.

    Minter M. R. Taylor J. M. Crack P. J. (2016 ). The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease. J. Neurochem. 136 457–474.

    Not in our library10.1111/jnc.13411

  31. 31.

    Montagne A. Barnes S. R. Sweeney M. D. Halliday M. R. Sagare A. P. Zhao Z. (2015 ). Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85 296–302.

    Not in our library10.1016/j.neuron.2014.12.032

  32. 32.

    Nishimori J. H. Newman T. N. Oppong G. O. Rapsinski G. J. Yen J. H. Biesecker S. G. (2012 ). Microbial amyloids induce interleukin 17A and IL-22 rvia TLR2 activation. Infect. Immun. 80 4398–4408.

    Not in our library10.1128/iai.00911-12

  33. 33.

    Richards R. I. Robertson S. A. O’Keefe L. V. Fornarino D. Scott A. Lardelli M. (2016 ). The enemy within: innate surveillance-mediated cell death, the common mechanism of neurodegenerative disease. Front Neurosci. 10:193

    Not in our library10.3389/fnins.2016.00193

  34. 34.

    Rogers M. A. Aronoff D. M. (2016 ). The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin. Microbiol. Infect. 22.e1–.e178.

    Not in our library10.1016/j.cmi.2015.10.003

  35. 35.

    Sampson T. R. Mazmanian S. K. (2016 ). Control of brain development, function, and behavior by the microbiome cell host microbe. Cell Host Microbe 17 565–576.

    Not in our library10.1016/j.chom.2015.04.011

  36. 36.

    Seksik P. Landman C. (2015 ). Understanding microbiome data: a primer for clinicians. Dig. Dis. 33(Suppl. 1) 11–16. [Epub ahead of print]

    Not in our library10.1159/000437034

  37. 37.
  38. 38.

    Seong E. Yuan L. Arikkath J. (2015 ). Cadherins and catenins in dendrite and synapse morphogenesis. Cell Adh. Migr. 9 202–213.

    Not in our library10.4161/19336918.2014.994919

  39. 39.

    Soenen S. Rayner C. K. Jones K. L. Horowitz M. (2016 ). The ageing gastrointestinal tract. Curr. Opin. Clin. Nutr. Metab. Care 19 12–18.

    Not in our library10.1097/mco.0000000000000238

  40. 40.

    van de Haar H. J. Burgmans S. Jansen J. F. van Osch M. J. van Buchem M. A. Muller M. (2016 ). Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology [Epub ahead of print].

    Not in our library10.1148/radiol.2016152244

  41. 41.

    Varatharaj A. Galea I. (2016 ). The blood-brain barrier in systemic inflammation. Brain Behav. Immun. [Epub ahead of print]

    Not in our library10.1016/j.bbi.2016.03.010

  42. 42.

    Youssef N. H. Couger M. B. McCully A. L. Criado A. E. Elshahed M. S. (2015 ). Assessing the global phylum level diversity within the bacterial domain: a review. J. Adv. Res. 6 269–282.

    Not in our library10.1016/j.jare.2014.10.005

  43. 43.

    Yu Y. Ye R. D. (2015 ). Microglial Aβ receptors in Alzheimer’s disease. Cell. Mol. Neurobiol. 35 71–83.

    Not in our library10.1007/s10571-014-0101-6

  44. 44.
  45. 45.
  46. 46.

    Zhao Y. Dua P. Lukiw W. J. (2015 ). Microbial sources of amyloid and relevance to amyloidogenesis and Alzheimer’s disease (AD). J. Alzheimers Dis. Parkinsonism 5 177.

    Not in our library10.4172/2161-0460.1000177

  47. 47.

    Zhao Y. Jaber V. Lukiw W. J. (2016 ). Over-expressed pathogenic miRNAs in Alzheimer’s disease (AD) and prion disease (PrD) drive deficits in TREM2-mediated Aβ42 peptide clearance. Fron. Aging Neurosci. 8:140

    Not in our library10.3389/fnagi.2016.00140

  48. 48.

    Zhao Y. Lukiw W. J. (2015 ). Microbiome-generated amyloid and potential impact on amyloidogenesis in Alzheimer’s disease (AD). J. Nat. Sci. 1:e138.

    Not in our library

Cited by papers we hold 18

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.